Get the Stockscreener App
7.97
1.40%
0.11
After Hours:
7.97
Evolus Inc stock is traded at $7.97, with a volume of 398.31K.
It is up +1.40% in the last 24 hours and down -11.20% over the past month.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
See More
Previous Close:
$7.86
Open:
$7.84
24h Volume:
398.31K
Relative Volume:
0.45
Market Cap:
$526.42M
Revenue:
$301.79M
Net Income/Loss:
$-43.42M
P/E Ratio:
-11.89
EPS:
-0.6705
Net Cash Flow:
$-44.87M
1W Performance:
+1.40%
1M Performance:
-11.20%
6M Performance:
+82.38%
1Y Performance:
+33.28%
1-Day Range:
$7.7118
$8.00
1-Week Range:
$7.7118
$8.51
52-Week Range:
$3.86
$9.31
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
7.97 | 526.42M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus Deadline Alert - TMX Newsfile
Discover Evolus And Two Other Growth Companies With Strong Insider Backing - webull.com
Evolus, Inc. (EOLS) Stock Analysis: Exploring an 87% Potential Upside in the Aesthetic Beauty Market - DirectorsTalk Interviews
Evolus Q2 2026 Earnings: EPS Turns Positive at $0.02, Beating Estimates by 156.82%Dividend Earnings Report - dars.gov.et
(EOLS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future - Yahoo Finance
Evolus Insider MOATAZEDI DAVID Sells 105,108 Shares at $9.04 Each (NASDAQ: EOLS) - Kalkine Media
Evolus president & CEO David Moatazedi sells $950,018 in shares By Investing.com - Investing.com UK
Evolus president & CEO David Moatazedi sells $950,018 in shares - Investing.com India
Evolus Officer Sold Shares Worth Over $950K - TradingView
Insider at Evolus (NASDAQ: EOLS) moves to sell nearly $1M in stock - Stock Titan
Evolus (EOLS) Advances 2.36% to $9.09, Holding Ground Above SupportRange Breakout - dars.gov.et
Evolus (EOLS) adds Soleus group as new 5.3% shareholder - Stock Titan
(EOLS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2 - Eastern Progress
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet - Eastern Progress
Evolus (EOLS) Earnings Update: The EPS Result Is Above Expectation in the Current Update; Market Response: Shares Move Higher 2.22% on the DayEarnings Decline Risk - vinanet.vn
Evolus (EOLS) Results Check: EPS Prints Above Forecast in the Latest Reading; Trading Move - vinanet.vn
EOLS | Evolus, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Evolus (EOLS) Quarter in Focus: EPS Comes in Above Forecast on the Day; Share Move: The Share Price Adds 5.28% in the Current UpdateRevenue Warning Signal - vinanet.vn
Evolus (EOLS) Quarter in Focus: EPS Comes in Above Forecast on the Day; Share Move - dars.gov.et
Evolus (EOLS) Closing Note: Records a 5.28% Increase to $8.18 in the Latest Session; the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordBearish Sentiment - vinanet.vn
EOLS Q2 2026 Earnings: EPS Turns Positive, Delivering 156.82% Surprise vs. EstimatesCost Structure Review - vinanet.vn
August 2026's Leading Growth Companies With Insider Confidence - Sahm
Midday Stock Roundup: Mobix Labs Shares Fall 21% at Midday - ocbj.com
Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS - marketbeat.com
Evolus, Inc. (EOLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS - marketbeat.com
EOLS Q2 2026 Earnings: EPS Surprises to the Upside as Shares SlipSlow Growth Warning - careplusvn.com
Evolus (NASDAQ:EOLS) Reaches New 1-Year HighHere's What Happened - MarketBeat
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade - Yahoo Finance
Evolus: The Injectable Platform Is Becoming The Real Moat (NASDAQ:EOLS) - Seeking Alpha
EOLS Q2 2026 Earnings: EPS of $0.02 Beats Estimates by 156.8% as Profitability Inflection EmergesNew Analyst Coverage - dars.gov.et
Trading Systems Reacting to (EOLS) Volatility - Stock Traders Daily
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - marketbeat.com
Needham Maintains Evolus(EOLS.US) With Hold Rating - moomoo.com
BTIG Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Evolus Inc (EOLS) Stock News Today - TradingKey
Evolus, Inc. (EOLS) Investor Outlook: Analyzing 97.93% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ... - Yahoo Finance
Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Su - GuruFocus
Earnings call transcript: Evolus tops revenue forecast in Q2 2026, shares rise - Investing.com UK
Evolus, Inc. Q2 2026 Financial Results: Revenue, Risks, and Key Business Updates - Minichart
Evolus Q2 Earnings Call Highlights - MarketBeat
Is Evolus Inc (EOLS) Undervalued After Q2 Earnings Beat? EPS: -0 - GuruFocus
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):